home > news > detailed info

Northway Biotechpharma and Memo Therapeutics AG sign a Development and Manufacturing Agreement

Northway Biotechpharma

Vilnius, Lithuania, and Zurich, Switzerland – June 25, 2020 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Swiss biotech company Memo Therapeutics AG have signed a Development and Manufacturing Agreement for a therapeutic antibody.

Memo Therapeutics AG aims to bring its lead Monoclonal Antibody MTX-005 for the immunotherapy of BK virus infection in kidney transplant recipients into clinical development in 2021. Northway Biotechpharma will develop the cell line and the manufacturing process, followed by cGMP manufacturing of Memo´s therapeutic antibody for clinical studies.

“Infection with the BK virus is a serious threat to kidney transplant patients. We have identified a BK virus-neutralizing antibody with ultra high potency isolated from human donors for the treatment of BK virus infection after kidney transplantation. We have chosen Northway Biotechpharma due to its technical capabilities and expertise which is very important for the successful production of our antibody”, said Dr. Karsten Fischer, CEO of Memo Therapeutics AG.

Dr. Vladas Bumelis, Executive Chairman of the Board of Northway Biotechpharma, commented “I am very excited to start the cooperation with Memo Therapeutics AG on this promising antibody, supporting Memo´s program from cell line development up to drug product manufacturing”.

“Northway Biotechpharma is perfectly positioned to act as Memo Therapeutics AG´ cooperation partner for this project due to its high quality approach, its proven track record with similar programs and its outstanding customer focus combined with CMC guidance”, said Dr. André Markmann, VP Business Development of Northway Biotechpharma.

About Northway Biotechpharma -

Northway Biotechpharma is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s wide-ranging expertise and vertically integrated service offering translates to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities, while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotechpharma is a privately owned company founded in 2004 and located in Vilnius, Lithuania, and in Waltham, Boston, US.

For Further Information Contact:

About Memo Therapeutics AG -

Memo Therapeutics AG (MTx) is an innovator in the field of antibody discovery and immune repertoire analysis.
MTx’s antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity. The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing mAbs with the desired functional properties. Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, the Company engages in antibody discovery across species and indications for proprietary and partnered projects.
MTx’s current pipeline features programs in infectious diseases and immuno-oncology.
MTx is a private company located in Bio-Technopark Zurich, Switzerland.

For Further Information Contact:
email Northway Biotechpharma Mokslininku str. 4 LT-08412 Vilnius, Lithuania
Print this page
Send to a friend
News and Press Releases

Stevanato Group signs an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to provide pharma glass vials for 2 billion doses of COVID-19 vaccines under development

More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor


The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement